About OUTLOOK THERAPEUTICS
Outlook Therapeutics (NASDAQ:OTLK) specializes in developing and delivering innovative treatments for ocular diseases. Focused primarily on advancing ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications, the company aims to address the critical needs of patients with eye diseases through rigorous research and targeted therapies. Their objective is not only to provide new, more accessible options for those suffering from conditions like wet age-related macular degeneration (wet AMD) but also to improve upon the safety and efficacy profiles of existing treatments. Engaged in clinical trials and regulatory processes, Outlook Therapeutics is committed to making a meaningful difference in the field of ophthalmology.
Snapshot
Operations
Produtos e/ou serviços de OUTLOOK THERAPEUTICS
- Development of ONS-5010 / LYTENAVA (bevacizumab-vikg), a proposed biosimilar to Avastin, aimed at treating wet age-related macular degeneration and other retinal diseases.
- Clinical trials for the efficacy and safety of ONS-5010 / LYTENAVA in treating branch retinal vein occlusion (BRVO), a significant cause of vision loss.
- Research into the use of ONS-5010 / LYTENAVA for treating diabetic macular edema (DME), focusing on improving vision and retinal health in diabetics.
- Preparation and submission of a Biologics License Application (BLA) to the FDA for ONS-5010 / LYTENAVA, targeting regulatory approval for commercialization.
- Partnership initiatives for the global commercialization of ONS-5010 / LYTENAVA, aiming to make the treatment available worldwide.
- Ongoing post-marketing studies to assure long-term efficacy and safety of their biosimilar products, ensuring patient safety and compliance with regulatory standards.
equipe executiva do OUTLOOK THERAPEUTICS
- Mr. Robert Charles JahrPresident, CEO & Director
- Mr. Lawrence A. Kenyon CPAEVP, CFO, Treasurer, Secretary & Director
- Mr. Joel PrieveSenior Vice President of Licensing and M&A
- Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs
- Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory Affairs
- Mr. Jedd ComiskeySenior VP - Head of Europe